MedTrace Logo

Observational Study of the Use of octaplasLG®.

NCT03369314 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 263

Last updated 2021-03-19

No results posted yet for this study

Summary

This observational study enrolls patients who have received at least one infusion of octaplasLG®. OctaplasLG® will be administered standard of care and observation occurs during the treatment and 24 hours after the end of treatment. Characteristics of the use of octaplasLG®, tolerance criteria, and efficacy criteria will be collected.

Conditions

  • Thrombotic Thrombocytopenic Purpura

Interventions

DRUG

octaplasLG®

Data will be collected in all patients who have received at least one infusion of octaplasLG®

Sponsors & Collaborators

  • Octapharma

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-02
Primary Completion
2021-01-14
Completion
2021-01-14
FDA Drug
Yes

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03369314 on ClinicalTrials.gov